COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,686 Articles (22,913 medRxiv, 8,773 bioRxiv)

Most recent first Previous |  Page 2291: Articles 22901-22910  | Next

Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19.
Salguero, F. J., White, A. D., Slack, G. S., Fotheringham, S. A., Bewley, K. R., Gooch, K. E., Longet, S., Humphries, H. E., Watson, R. J., Hunter, L., Ryan, K. A., Hall, Y., Sibley, L., Sarfas, C., Allen, L., Aram, M., Brunt, E., Brown, P., Buttigieg, K. R., Cavell, B. E., Cobb, R., Coombes, N. S., Daykin-Pont, O., Elmore, M. J., Gkolfinos, K., Godwin, K. J., Gouriet, J., Halkerston, R., Harris, D. J., Hender, T., Ho, C. M. K., Kennard, C. L., Knott, D., Leung, S., Lucas, V., Mabbutt, A., Morrison, A. L., Ngabo, D., Paterson, J., Penn, E. J., Pullan, S., Taylor, I., Tipton, T., Thomas, S., Tree, J. A., Turner, C., Wand, N., Wiblin, N. R., Charlton, S., Hallis, B., Pearson, G., Rayner, E. L., Nicholson, A. G., Funnell, S. G., Dennis, M. J., Gleeson, F. V., Sharpe, S., Carroll, M. W.
10.1101/2020.09.17.301093 — Posted: 2020-09-17
Identification of novel antiviral drug combinations in vitro and tracking their development
Ianevski, A., Yao, R., Biza, S., Zusinaite, E., Mannik, A., Kivi, G., Planken, A., Kurg, K., Tombak, E.-M., Ustav, M., Shtaida, N., Kulesskiy, E., Jo, E., Yang, J., Lysvand, H., Loseth, K., Oksenych, V., Aas, P. A., Tenson, T., Vitkauskiene, A., Windisch, M. P., Fenstad, M. H., Nordbo, S. A., Ustav, M., Bjoras, M., Kainov, D. E.
10.1101/2020.09.17.299933 — Posted: 2020-09-17
A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture
Tada, T., Fan, C., Kaur, R., Stapleford, K. A., Gristick, H., Nimigean, C., Landau, N. R.
10.1101/2020.09.16.300319 — Posted: 2020-09-17
Distinct SARS-CoV-2 Antibody Reactivity Patterns in Coronavirus Convalescent Plasma Revealed by a Coronavirus Antigen Microarray
Ramiro de Assis, R., Jain, A., Nakajima, R., Jasinskas, A., Khan, S., Dumont, L. J., Kelly, K., Simmons, G., Stone, M., Di Germanio, C., Busch, M. P., Felgner, P. L.
10.1101/2020.09.16.300871 — Posted: 2020-09-17
Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis
Boumaza, A., Gay, L., Mezouar, S., Diallo, A. B., Michel, M., Desnues, B., Raoult, D., LA SCOLA, B., Halfon, P., Vitte, J., Olive, D., Mege, J.-L.
10.1101/2020.09.17.300996 — Posted: 2020-09-17 Discussion: Onsite | Offsite
Estimating Risk of Mechanical Ventilation and Mortality Among Adult COVID-19 patients Admitted to Mass General Brigham: The VICE and DICE Scores
Nicholson, C. J., Wooster, L., Sigurslid, H. H., Li, R. F., Jiang, W., Tian, W., Cardenas, C. L., Malhotra, R.
10.1101/2020.09.14.20194670 — Posted: 2020-09-17
Positive selection within the genomes of SARS-CoV-2 and other Coronaviruses independent of impact on protein function
Berrio, A., Gartner, V., Wray, G. A.
10.1101/2020.09.16.300038 — Posted: 2020-09-16
Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro
Jang, M., Park, Y.-I., Park, R., Cha, Y.-E., Namkoong, S., Lee, J. I., Park, J.
10.1101/2020.09.16.299800 — Posted: 2020-09-16 Discussion: Onsite
Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors
Ma, C., Hu, Y., Townsend, J. A., Lagarias, P., Marty, M. T., Kolocouris, A., Wang, J.
10.1101/2020.09.15.299164 — Posted: 2020-09-16
Evaluation of nafamostat mesylate safety and inhibition of SARS-CoV-2 replication using a 3-dimensional human airway epithelia model
Kirkpatrick, L., Millard, J.
10.1101/2020.09.16.300483 — Posted: 2020-09-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).